---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-008989"
form_type: "8-K"
ticker: "ATXI"
cik: "0001644963"
company_name: "AVENUE THERAPEUTICS, INC."
filed_at: "2023-02-01T23:59:59+00:00"
generated_at: "2026-06-20T03:52:20.202582+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Avenue Therapeutics closes $3.25M equity raise; existing warrants repriced to $1.55

## Summary
- Raised ~$3.25M gross via registered direct offering of 1,940,299 shares and pre-funded warrants, plus private placement of 1,940,299 warrants.
- Private placement warrants priced at $0.125 each, exercise price $1.55, 3-year term from initial exercise date; subject to registration.
- Existing warrants (exp. Oct 2027) exercise price reduced from $3.30 to $1.55 effective Jan 27, 2023.
- Executives, directors and 10%+ holders subject to 90-day lock-up from closing date (Jan 31, 2023).
- Net proceeds to be used for working capital and general corporate purposes.

## SEC filing metadata
- accession: 0001104659-23-008989
- form_type: 8-K
- ticker: ATXI
- cik: 0001644963
- company_name: AVENUE THERAPEUTICS, INC.
- filed_at: 2023-02-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1644963/000110465923008989/0001104659-23-008989-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1644963/000110465923008989/tm234660d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-008989
- JSON: https://secwatch.observer/filing/0001104659-23-008989.json
- Plain text: https://secwatch.observer/filing/0001104659-23-008989.txt

## Key facts
- Material Agreements
  AVENUE THERAPEUTICS, INC. entered into Registered Purchase Agreement with a single institutional accredited investor valued at approximately $3.0 million (effective 2023-01-27).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: a single institutional accredited investor
  - Value: approximately $3.0 million
  - Effective: 2023-01-27
  source text: On January 27, 2023, Avenue Therapeutics, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Registered Purchase Agreement ”) with a single institutional accredited investor
  evidence_url: https://www.sec.gov/Archives/edgar/data/1644963/000110465923008989/0001104659-23-008989-index.htm
- Material Agreements
  AVENUE THERAPEUTICS, INC. entered into Placement Agent Agreement with Aegis Capital Corp. (effective 2023-01-27).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Aegis Capital Corp.
  - Effective: 2023-01-27
  source text: Aegis Capital Corp. (“ Aegis ”) acted as the exclusive placement agent in connection with the Registered Offering and the Private Placement under a Placement Agent Agreement, dated as of January 27, 2023, between the Company and Aegis (the “ Placement Agent Agreement ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1644963/000110465923008989/0001104659-23-008989-index.htm
- Material Agreements
  AVENUE THERAPEUTICS, INC. entered into Registration Rights Agreement with the investor (effective 2023-01-27).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: the investor
  - Effective: 2023-01-27
  source text: In connection with the PIPE Purchase Agreement, the Company entered into a registration rights agreement (the “ Registration Rights Agreement ”) with the investor.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1644963/000110465923008989/0001104659-23-008989-index.htm
- Material Agreements
  AVENUE THERAPEUTICS, INC. entered into PIPE Purchase Agreement with the same institutional accredited investor valued at approximately $0.24 million (effective 2023-01-27).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: the same institutional accredited investor
  - Value: approximately $0.24 million
  - Effective: 2023-01-27
  source text: On January 27, 2023, the Company also entered into a Securities Purchase Agreement (the “ PIPE Purchase Agreement ”) with the same institutional accredited investor
  evidence_url: https://www.sec.gov/Archives/edgar/data/1644963/000110465923008989/0001104659-23-008989-index.htm
- Material Agreements
  AVENUE THERAPEUTICS, INC. entered into Lock-Up Agreement with each of the Company’s executive officers, directors and the holders of 10% or more of the Company’s outstanding shares of Common Stock (effective 2023-01-27).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: each of the Company’s executive officers, directors and the holders of 10% or more of the Company’s outstanding shares of Common Stock
  - Effective: 2023-01-27
  source text: Each of the Company’s executive officers, directors and the holders of 10% or more of the Company’s outstanding shares of Common Stock entered into a lock-up agreement (the “ Lock-Up Agreement ”) pursuant to which they agreed not to sell or transfer any securities of the Company held by them for a period commencing on January 27, 2023 and ending ninety (90) days after the Effective Date (as defined in PIPE Purchase Agreement), subject to limited exceptions.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1644963/000110465923008989/0001104659-23-008989-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.